A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as Compared to Abiraterone Acetate

Key facts

Study ID

NCT02737332

Run by

Sun Pharmaceutical Industries Limited

People needed

53

Starts

2016-03-21

Expected to finish

2017-02-27

Last updated by the study team

2021-11-22

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent obtained prior to any study-related procedure being performed
• Male subjects at least 18 years of age or older at time of consent
• Pathologically confirmed adenocarcinoma of the prostate
• Ongoing therapy with a GnRH agonist or antagonist AND serum testosterone level <50 ng/dL at screening
• Metastatic disease documented by computed tomography (CT)/ magnetic resonance imaging (MRI) or bone scan. Imaging obtained within 42 days prior to the start of study medication will be accepted.
• Meeting disease progression according to the recommendations of the prostate cancer working group 2 by one of the following criteria:
• Two rises of PSA (taken a minimum of 1 week apart) from a baseline measurement of at least 2 ng/mL,
• Imaging progression (CT/MRI) by RECIST criteria
• Nuclear scan progression by new lesion.
• Discontinuation of flutamide or nilutamide, and other anti-androgens at least 4 weeks prior to the start of study medication; discontinuation of bicalutamide at least 6 weeks prior to start of study medication.
• Discontinuation of Radiotherapy > 4 weeks prior to start of study medication.
• ECOG performance status of 0-1 at screening
• Screening blood counts of the following:
• Absolute neutrophil count > 1500/µL
• Platelets > 100,000/µL
• Hemoglobin > 9 g/dL
• Screening chemistry values of the following:
• ALT and AST < 2.5 x ULN
• Total bilirubin < 1.5 x ULN
• Creatinine< 1.5 x ULN
• Albumin > 3.0 g/dL
• Potassium > 3.5 mmol/L
• Life expectancy of at least 6 months at screening
• Subject is willing and able to comply with all protocol requirements assessments
• Agrees to protocol-defined use of effective contraception.

You may not qualify if…

• History of impaired pituitary or adrenal gland function
• Prior therapy with abiraterone acetate, orteronel, ketoconazole or any other CYP17 inhibitor
• Prior therapy with enzalutamide
• Prior use of experimental androgen receptor antagonist
• Previous exposure to Ra-223:Xofigo
• Previous chemotherapy
• Initiation of bisphosphonate or denosumab therapy within 30 days prior to the start of study medication. Patients who are on a stable dose of these medications for at least 30 days at the time of starting study drug are eligible.
• Therapy with estrogen within 30 days prior to the start of study medication
• Use of systemic glucocorticoids equivalent to > 10 mg of prednisone daily; patients who have discontinued or have reduced dose to < 10 mg prednisone within 14 days prior to the start of study medication will be eligible
• Prior use of any herbal products that may decrease PSA levels (eg., saw palmetto) within 30 days of start of study medication
• Known metastases to the brain or CNS involvement
• History of other malignancy within the previous 2 years
• Major surgery within 30 days prior to the start of study medication
• Blood transfusion within 30 days of screening
• Serious, persistent infection within 14 days of the start of study medication
• Persistent pain that requires the use of a narcotic analgesic
• Known gastrointestinal disease or condition that may impair absorption
• Treatment with any investigational drug within 4 weeks prior to Day -1 of the study.
• Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus
• Have poorly controlled diabetes.
• Uncontrolled hypertension
• History of New York Heart Association (NYHA) class III or IV heart failure
• Serious concurrent illness, including psychiatric illness, that would interfere with study participation
• Inability to swallow tablets whole
• Known hypersensitivity to any excipients in study medications

Where it is running

• Alliance Research — Laguna Hills, California, United States
• Tower Urology — Los Angeles, California, United States
• San Bernardino Urological — San Bernardino, California, United States
• Skyline Urology — Torrance, California, United States
• Innovative Clinical Research Institute — Whittier, California, United States
• Urology Associates, P.C. — Englewood, Colorado, United States
• Manatee Medical Research — Bradenton, Florida, United States
• North Idaho Urology — Coeur d'Alene, Idaho, United States
• The Iowa Clinic — West Des Moines, Iowa, United States
• Wichita Urology Group — Wichita, Kansas, United States
• Chesapeake Urology Research Associates — Towson, Maryland, United States
• Lincoln Urology, PC — Lincoln, Nebraska, United States
• Urology Cancer Center — Omaha, Nebraska, United States
• Brooklyn Urology Research Group — Brooklyn, New York, United States
• Associated Urologist of North Carolina — Raleigh, North Carolina, United States
• Urology Clinics of North Texas — Dallas, Texas, United States
• Urology of Virginia — Virginia Beach, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.